Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine
Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine. Antimicrobial Agents And Chemotherapy 2011, 55: 5893-5899. PMID: 21968368, PMCID: PMC3232750, DOI: 10.1128/aac.00387-11.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAminoglycosidesAnti-Bacterial AgentsCarbapenemsCohort StudiesDrug Resistance, BacterialFemaleHumansKlebsiella InfectionsKlebsiella pneumoniaeMaleMicrobial Sensitivity TestsMiddle AgedMinocyclinePolymyxin BRetrospective StudiesTigecyclineTreatment OutcomeUrinary Tract InfectionsUrineYoung AdultConceptsCarbapenem-resistant Klebsiella pneumoniaePolymyxin BCRKP bacteriuriaMicrobiologic clearanceUntreated cohortHealth care-associated urinary tract infectionsClearance rateKlebsiella pneumoniaeRetrospective cohort studyUrinary tract infectionNew York Presbyterian HospitalCohort studyTract infectionsUrine cultureAntimicrobial therapyAppropriate followCommon causeActive agentsMultiple active agentsTigecyclineComparative effectivenessMultivariate analysisCohortGram-negative activityAminoglycosidesMolecular Markers of Response to Treatment for Melanoma
Sznol M. Molecular Markers of Response to Treatment for Melanoma. The Cancer Journal 2011, 17: 127-133. PMID: 21427556, DOI: 10.1097/ppo.0b013e318212dd5a.Peer-Reviewed Original ResearchConceptsImmune therapyAnti-tumor immune responseInitial high response rateStandard of careFraction of patientsUseful predictive biomarkerHigh response rateMost patientsMetastatic melanomaPredictive biomarkersClinical activityImmune responseIndividual patientsPotent small molecule inhibitorsDurable benefitMultiple active agentsSmall molecule inhibitorsResponse ratePatientsMutant BRAFOverall populationTherapyMolecule inhibitorsMelanomaTumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply